t
The Pennycook Family Trust, controlled by Ondine Biomedical Inc. CEO Carolyn Cross and Robert Cross, purchased 100,000 Common Shares in Ondine Biomedical Inc. at 12.5 pence per share on 31 January 2025. Following this transaction, Carolyn Cross and Robert Cross directly and indirectly hold 156,164,804 Common Shares, representing 35.3284% of the Company's issued share capital.
| Date | 3 Feb 2025 |
| Time | 08:00:00 |
| Category | Director/PDMR dealings |
| ID | 5598V |
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or the "Company")
Ondine CEO adds to stake in Company as Phase 3 clinical trial progresses
Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that The Pennycook Family Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband of Carolyn Cross, has purchased 100,000 shares ("Common Shares") in the Company at a price of 12.5 pence per Common Share on 31 January 2025.
Following this transaction, Carolyn Cross and Robert Cross, directly and indirectly, hold 156,164,804 Common Shares representing 35.3284%% of the issued share capital of the Company.
Enquiries:
|
Ondine Biomedical Inc. |
|
|
Carolyn Cross, CEO |
Via Vane Percy & Roberts |
|
Strand Hanson Limited (Nominated & Financial Adviser) |
|
|
James Harris, Richard Johnson |
+44 (0)20 7409 3494 |
|
|
|
|
RBC Capital Markets (Broker) |
|
|
Rupert Walford, Kathryn Deegan |
+44 (0)20 7653 4000 |
|
|
|
|
Vane Percy & Roberts (Media Contact) |
|
|
Simon Vane Percy, Amanda Bernard |
+44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Carolyn Cross and her PCA |
|
2. |
Reason for the Notification |
|
|
a) |
Position/status |
Chief Executive Officer (PDMR) |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Ondine Biomedical Inc. |
|
b) |
LEI |
9845005B69E07CGF4A56 |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the Financial instrument, type of instrument
|
Common shares |
|
Identification code |
ISIN: CA68234M2058 |
|
|
b) |
Nature of the transaction |
Share purchase |
|
c) |
Price(s) and volume(s) |
100,000 shares at 12.5 pence each |
|
d) |
Aggregated information: ·Aggregated volume ·Price |
N/A
|
|
e) |
Date of the transaction |
31 January 2025 |
|
f) |
Place of the transaction |
AIM |